Headquartered in Parma since 1935, Chiesi is an international company with more than 85 years of experience and a strong focus on research, development, production and the commercialization of innovative medicines in the Respiratory, Neonatology, Rare Diseases and Special Care Therapeutic Areas. Our production sites are in Parma, Italy, Blois (France) and Santana De Parnaiba (Brazil). The R&D centers in Parma (Italy), Paris (France), Cary (USA), Chippenham (UK) and the R&D team from the acquired Danish company Zymenex, integrate their efforts to advance Chiesi's pre-clinical, clinical and registration programs. We export to more than 70 countries with a direct presence in 26. Our aim is to be recognized as a research-focused international Group, able to develop and commercialize innovative pharmaceutical solutions to improve the quality of human life. As a B Corp in the biopharmaceutical industry, Chiesi is counted among businesses that are leading a global movement for an inclusive, equitable, and regenerative economy. We are committed to improving patient quality of life, protecting the planet and its inhabitants, supporting our communities, promoting the development of our people and guaranteeing maximum transparency in the way we work. Chiesi Hellas was established in 1998 and has a strong presence in the Greek pharmaceutical market with high rates of growth. Chiesi Hellas invests in its people and operates under the principles of fairness, equality and inclusion. We are committed to achieving results, while operating with integrity, in a socially and environmentally responsible manner. PHARMACOVIGILANCE: For any report regarding the safety of our products, as well as for Medical information, you can contact the Pharmacovigilance Department: Tel. (+30) 210 6179763 e-mail: pharmacovigilance.gr@chiesi.com